Recce Pharmaceuticals Ltd - Asset Resilience Ratio
Recce Pharmaceuticals Ltd (RCE) has an Asset Resilience Ratio of 1.91% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read RCE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Recce Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See Recce Pharmaceuticals Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Recce Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Recce Pharmaceuticals Ltd (RCE) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$236.63K | 1.91% |
| Total Liquid Assets | AU$236.63K | 1.91% |
Asset Resilience Insights
- Limited Liquidity: Recce Pharmaceuticals Ltd maintains only 1.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Recce Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Recce Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Recce Pharmaceuticals Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Recce Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 1.91% | AU$236.63K ≈ $167.43K |
AU$12.41 Million ≈ $8.78 Million |
-1.36pp |
| 2024-06-30 | 3.26% | AU$207.86K ≈ $147.07K |
AU$6.37 Million ≈ $4.51 Million |
+1.42pp |
| 2023-06-30 | 1.84% | AU$47.00K ≈ $33.26K |
AU$2.56 Million ≈ $1.81 Million |
+1.68pp |
| 2022-06-30 | 0.16% | AU$20.10K ≈ $14.22K |
AU$12.62 Million ≈ $8.93 Million |
-59.27pp |
| 2018-06-30 | 59.43% | AU$679.72K ≈ $480.95K |
AU$1.14 Million ≈ $809.27K |
-15.02pp |
| 2017-06-30 | 74.45% | AU$1.09 Million ≈ $771.56K |
AU$1.46 Million ≈ $1.04 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$3.72 Million ≈ $2.63 Million |
-- |
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary… Read more